Does Medicare Cover GLP-1 Drugs? (2026)

Direct Answer

It depends on why the GLP-1 is prescribed. Medicare Part D has covered GLP-1 drugs like Ozempic and Mounjaro for Type 2 diabetes for years. Original Medicare Part B never covers GLP-1 drugs, since self-administered prescriptions are a Part D benefit. Starting July 1, 2026, the CMS GLP-1 Bridge demonstration adds limited weight-loss coverage: eligible Part D enrollees pay a $50 monthly copay for Foundayo, Wegovy, or Zepbound through December 31, 2027.

Medicare and GLP-1 Drugs for Diabetes (Part D)

Medicare Part D plans have included GLP-1 receptor agonists on their diabetes formularies since each drug's FDA approval: Ozempic and Rybelsus (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide), and Victoza (liraglutide) are all approved for Type 2 diabetes management and appear on most 2026 Part D formularies, typically on Tier 2 or Tier 3. Medicare Advantage plans with drug coverage (MA-PD) follow the identical Part D formulary rules, so the diabetes coverage question is the same regardless of whether you have a standalone Part D plan or an MA-PD plan.

Original Medicare (Part A and Part B) does not cover any of these drugs directly, because self-administered injectable or oral prescriptions are a Part D pharmacy benefit, not a Part A hospital benefit or a Part B medical benefit. Prior authorization and step therapy (trying metformin or another oral agent first) are common plan requirements before a GLP-1 is approved for diabetes, and coinsurance for these drugs counts toward the 2026 Part D out-of-pocket cap of $2,100.

Why Weight-Loss GLP-1 Coverage Has Been Limited

The Medicare Modernization Act of 2003 created Part D but wrote in a categorical exclusion for anti-obesity drugs and anorexiants, codified at Social Security Act Section 1927(d)(2)(A). That statute means Part D plans cannot cover a GLP-1 when the prescription's stated purpose is weight loss alone, regardless of what a plan's formulary lists. Ozempic and Mounjaro carry Medicare-relevant approvals only for Type 2 diabetes, so those two brands are never covered for weight loss under any current exception. This is a meaningful contrast with ACA-compliant marketplace plans, which under the ACA's essential health benefits rules cannot deny GLP-1 coverage for diabetes based on a preexisting condition; Medicare's exclusion is drug-purpose-specific, not condition-specific.

Three Paths to Weight-Loss Coverage in 2026

Three exceptions now sit outside the 2003 statutory exclusion, and each requires a specific diagnosis, not just a weight-loss goal. Wegovy (semaglutide 2.4 mg) is covered when a Medicare beneficiary has established cardiovascular disease and a prescription written for reducing major adverse cardiovascular events (MACE), a pathway CMS confirmed in March 2024 after the FDA's cardiovascular-risk approval. Zepbound (tirzepatide) is covered when prescribed for moderate-to-severe obstructive sleep apnea confirmed by a sleep study in a patient with obesity, following the FDA's December 2024 OSA approval.

The third path, the Medicare GLP-1 Bridge program, runs July 1, 2026 through December 31, 2027 and covers weight management directly, without requiring a cardiovascular or sleep apnea diagnosis, for beneficiaries who meet BMI-based criteria. These three paths are separate and do not require each other: a beneficiary can qualify through only one.

The 2026 GLP-1 Bridge Program: Eligibility and Cost

The Bridge program covers Foundayo (orforglipron tablet), Wegovy (injection or tablet), and Zepbound in the KwikPen formulation only; single-dose Zepbound pens and vials are excluded. To qualify, a beneficiary must be at least 18, enrolled in Part D or an MA-PD plan, not already have Type 2 diabetes, and not already be receiving a GLP-1 through their plan. Beneficiaries must also meet one of three BMI-based thresholds.

• BMI of 35 or higher, on its own
• BMI of 30 or higher plus a qualifying condition: diastolic heart failure, uncontrolled hypertension, or stage 3a or higher chronic kidney disease
• BMI of 27 or higher plus prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease
• The copay is $50 for a 30-day supply and does not count toward the 2026 Part D out-of-pocket cap of $2,100
• The program runs July 1, 2026 through December 31, 2027 and reverts to the prior rules unless Congress extends it

What GLP-1 Drugs Cost Without Medicare Coverage in 2026

Outside a covered pathway, GLP-1 list prices remain high in 2026: Ozempic runs about $1,000 per month at retail, Wegovy lists at roughly $1,350 per month (Novo Nordisk has announced a cut to $675 starting January 2027), and Zepbound's manufacturer list price ranges from about $499 to $1,086 for a 28-day supply depending on dose. Manufacturer self-pay cash programs bring the price down substantially for beneficiaries willing to pay out of pocket: LillyDirect prices Zepbound single-dose vials from roughly $299 to $449 per month, and NovoCare prices Wegovy from about $199 to $349 per month depending on dose and refill timing.

Alternatives If Medicare Doesn't Cover Your GLP-1

If none of the three weight-loss pathways apply to you, five options remain. Each is worth checking before paying full list price.

• Manufacturer self-pay programs: LillyDirect and NovoCare sell GLP-1s directly at cash prices well below list price. These are open to Medicare beneficiaries because they are direct-purchase programs, not insurance copay coupons (which federal law bars from use with Medicare).
• Ask your doctor about a covered indication: if you have established cardiovascular disease or a sleep-study-confirmed OSA diagnosis, a correctly coded prescription may qualify for the Wegovy or Zepbound exceptions instead of the Bridge program.
• Dual-eligible Medicaid coverage: Medicaid is not bound by the Part D anti-obesity exclusion, and several states cover GLP-1s for obesity under their Medicaid drug benefit. Check state rules if you qualify for both programs.
• State Pharmaceutical Assistance Programs (SPAPs): a small number of states run supplemental drug assistance programs for Medicare beneficiaries that can lower GLP-1 out-of-pocket costs.
• Avoid compounded semaglutide or tirzepatide from non-licensed sources: the FDA has warned that compounded versions sold outside state-licensed pharmacies carry dosing and contamination risks, and they are not eligible for any Medicare or manufacturer program.

Does Medicare cover Ozempic for diabetes in 2026?

Yes. Ozempic (semaglutide) is FDA-approved for Type 2 diabetes and appears on most Medicare Part D formularies in 2026, typically on Tier 2 or Tier 3, subject to prior authorization or step therapy. Medicare Advantage plans with drug coverage follow the same rules. Original Medicare Part B never covers Ozempic because self-administered drugs are a Part D benefit, not a medical benefit.

Does Medicare cover Wegovy for weight loss?

Only through a specific pathway. Wegovy is covered when prescribed to reduce major adverse cardiovascular events in a beneficiary with established cardiovascular disease, a rule CMS confirmed in March 2024. It is also covered through the Medicare GLP-1 Bridge program from July 1, 2026 through December 31, 2027 for beneficiaries meeting BMI-based criteria. Outside those two paths, Wegovy for weight loss alone is excluded by the 2003 Medicare Modernization Act.

What is the Medicare GLP-1 Bridge program and who qualifies?

The Bridge program is a temporary CMS demonstration running July 1, 2026 through December 31, 2027 that covers Foundayo, Wegovy, and Zepbound KwikPens for weight management at a $50 monthly copay. To qualify, you must be at least 18, enrolled in Part D or an MA-PD plan, not have Type 2 diabetes, and meet a BMI threshold of 35+, or 30+ with a qualifying condition, or 27+ with prediabetes or cardiovascular history.

Does Medicare cover Zepbound for sleep apnea?

Yes, when prescribed for moderate-to-severe obstructive sleep apnea confirmed by a sleep study in a patient with obesity. The FDA approved this indication for Zepbound in December 2024, and it sits outside the Part D anti-obesity drug exclusion because the diagnosis is OSA, not weight loss. This is separate from the 2026-2027 Bridge program and does not expire with it.

How much do GLP-1 drugs cost without Medicare coverage in 2026?

List prices remain high: Ozempic runs about $1,000 per month, Wegovy about $1,350 per month, and Zepbound's manufacturer list price ranges from roughly $499 to $1,086 for a 28-day supply depending on dose. Manufacturer self-pay cash programs bring costs down: LillyDirect prices Zepbound vials from about $299 to $449 per month, and NovoCare prices Wegovy from about $199 to $349 per month.

Does Medicare Advantage cover GLP-1 drugs differently than Original Medicare?

No. Medicare Advantage plans with drug coverage (MA-PD) follow the exact same Part D formulary rules and the same three weight-loss exceptions as standalone Part D plans. The real difference is Original Medicare Part A and Part B, neither of which ever covers self-administered GLP-1 drugs regardless of diagnosis, since that coverage always runs through the Part D drug benefit.

Can I use a manufacturer coupon with Medicare for GLP-1 drugs?

Insurance-style manufacturer copay coupons generally cannot be used with Medicare because federal anti-kickback rules bar drugmakers from subsidizing cost-sharing for federal health program beneficiaries. However, LillyDirect and NovoCare's cash self-pay programs are direct-purchase pricing, not insurance coupons, so Medicare beneficiaries can use them to buy GLP-1 drugs outright at reduced cash prices.

What happens to GLP-1 weight-loss coverage after the Bridge program ends in 2027?

The Bridge program expires December 31, 2027, and coverage reverts to the pre-Bridge rules (the cardiovascular and sleep apnea exceptions only) unless Congress passes legislation changing Section 1927(d)(2)(A) of the Social Security Act. Bills addressing this have been introduced in Congress but had not passed as of late 2026. Watch medicare.gov for updates before the program's end date.